

Kindly add the following claims:

24. (New) The compound of claim 1 wherein the compound is capable of binding to human MDM2.

a5
25. (New) The compound of claim 1 wherein the compound inhibits the binding of MDM2 to p53.

26. (New) The compound of claim 25 wherein the inhibition blocks the binding of MDM2 to p53.

ADD D17

REMARKS

New claims 24-26 have been added. Claim 12 has been deleted. Claims 1, 5-7, 8-11, 13-18, 22 and 23 have been amended. No new matter has been added by these amendments.

A substitute sequence listing has been provided along with a Computer Readable Form of the Sequence Listing. The undersigned hereby states that the Paper Copy and the Computer Readable Form, submitted in accordance with 37 CFR 1.821 include no new matter and are identical. The specification has been amended to include the sequence listing numbers with the corresponding sequences. New sequence number 83 has been added to the Sequence Listing. This sequence can be found in the originally filed specification at page 30, line 14.

Favorable consideration of this application is respectfully requested.

Respectfully submitted,

Novartis Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027
(908) 522-6938

Myra McCormack

Myra H. McCormack, Ph.D.
Attorney for Applicants
Reg. No. 36,602

Date: *January 5, 1999*